Skip to main content

Artificial pancreas systems

Artificial pancreas systems

05-19-2023 | Type 1 diabetes | News

Over 60s with type 1 diabetes show trust in Cambridge hybrid closed-loop system

The use of the Cambridge hybrid closed-loop insulin delivery system by older adults with type 1 diabetes mellitus is associated with “improved quality of life,” says an international team of researchers.

03-30-2023 | Artificial pancreas systems | News

Virtual closed-loop initiation success in very young children

The Tandem Control-IQ system delivers improved glucose control versus standard care in children with type 1 diabetes aged between 2 and 6 years and can be initiated virtually, report researchers.

11-30-2022 | Artificial pancreas systems | News

Real-world data show reduced diabetes burden in young closed-loop users

Real-world use of hybrid closed-loop insulin delivery is associated with improved glycemic control and sleep quality, as well as reduced fear of hypoglycemia in children and young people with type 1 diabetes, shows a UK study.

09-23-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

Illustration showing CGM communicating with Insulin Pump

09-20-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Fully closed-loop control boosts TIR in insulin-treated type 2 diabetes

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

09-07-2022 | Pathogenesis | News

CLOuD: Early and sustained closed-loop therapy does not stave off beta-cell decline

Starting young people on closed-loop insulin delivery within 21 days after type 1 diabetes diagnosis does not slow the decline in their C-peptide levels over the next 12 months, report the CLOuD investigators.

09-07-2022 | Artificial pancreas systems | News

AHCL system benefits people with poorly controlled type 1 diabetes

Use of the MiniMed 780G advanced hybrid closed-loop system leads to greater reductions in glycated hemoglobin levels than conventional treatment in people with poorly controlled type 1 diabetes, ADAPT study data show.

09-06-2022 | Artificial pancreas systems | News

Closed-loop control may support neurodevelopment in adolescents

Improved glycemic control with hybrid closed-loop insulin delivery may facilitate the typical neurodevelopmental changes that occur during adolescence for those with type 1 diabetes, suggests a proof-of-concept trial.

07-06-2022 | Artificial pancreas systems | News

Hybrid closed-loop system brings benefits even with lax bolusing

Use of the Tandem Control IQ hybrid closed-loop insulin delivery system improves time in range even for users who very rarely bolus for meals or to treat hyperglycemia, an observational study suggests.

06-13-2022 | Artificial pancreas systems | News

Researchers calculate unannounced snack threshold for closed-loop system

Children and adolescents using an advanced hybrid closed-loop system for type 1 diabetes can tolerate an unannounced snack containing 20 g of carbohydrate without excessive blood sugar fluctuations, Italian researchers report.

06-08-2022 | ADA 2022 | Conference coverage | News

OpenAPS closed-loop algorithm improves glucose control in formal trial

Closed-loop insulin delivery with the open-source OpenAPS algorithm results in significantly better glucose control than sensor-augmented pump delivery in children and adults in the randomized CREATE trial.

06-05-2022 | ADA 2022 | Conference coverage | News

Success of Omnipod 5 closed-loop system in preschoolers continues at 1 year

The Omnipod 5 closed-loop, tubeless insulin delivery system has achieved good results in young children with type 1 diabetes over 12 months, with no cases of severe hypoglycemia or diabetic ketoacidosis recorded.

06-04-2022 | ADA 2022 | Conference coverage | News

Bionic pancreas removes math from diabetes

The iLet bionic pancreas closed-loop insulin delivery system provides good glucose control without the need for the user to count carbohydrates, show findings from the pivotal trial.

05-18-2022 | Empagliflozin | News

Pros and cons with empagliflozin addition to closed-loop insulin

Adding daily empagliflozin to closed-loop insulin delivery improves time in range but also increases ketone levels in people with type 1 diabetes, shows a randomized trial.

05-04-2022 | Artificial pancreas systems | Conference coverage | News

Real-world study probes artificial pancreas system differences

Italian researchers have compared outcomes of children and adults with type 1 diabetes using Medtronic MiniMed 780G and the Tandem Control IQ closed-loop insulin delivery systems in real-world practice.

03-15-2022 | Artificial pancreas systems | News

High use, improved glucose control in older adults with Cambridge closed-loop system

Older adults with type 1 diabetes spend more time in target glucose range when using the Cambridge hybrid closed-loop insulin delivery system than when using sensor-augmented pump delivery, shows a randomized trial.

01-19-2022 | Artificial pancreas systems | News

Closed-loop benefits differ with high or low baseline HbA1c

Researchers find that the type of benefits people with type 1 diabetes gain from hybrid closed-loop insulin delivery differs according to their baseline glycemic control.

12-14-2021 | Artificial pancreas systems | News

Older age ‘not a barrier’ to closed-loop insulin delivery for type 1 diabetes

Findings from the ORACL trial suggest that closed-loop insulin delivery results in better glycemic control than sensor-augmented pump therapy among older adults with longstanding type 1 diabetes.

11-23-2021 | Artificial pancreas systems | News

Consensus statement on open-source closed-looping published

A consensus statement published in The Lancet Diabetes & Endocrinology offers information and guidance for healthcare practitioners faced with a person using DIY closed-loop insulin delivery.

11-03-2021 | Artificial pancreas systems | News

Glycemic, life quality benefits of hybrid closed loop shown in young people

Hybrid closed-loop therapy significantly improves glycemic control and quality of life relative to continuous subcutaneous insulin infusion or multiple daily insulin injections in children and adolescents with type 1 diabetes, research shows.